OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL

Leukemia Research

Volumn 27, Issue 11, 2003, Pages 1039-1050

  Tomkinson, Blake ^a   Bendele, Ray ^a   Giles, Francis J ^b   Brown, Eric ^a   Gray, Atherton ^c   Hart, Karen ^a   LeRay, Jeremy D ^a   Meyer, Denny ^a   Pelanne, Michelle ^a   Emerson, David L ^a  

^a OSI PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c PRINCESS MARGARET HOSPITAL   (United Kingdom)

Author keywords

ALL; AML; Antileukemia; OSI 211; Topoisomerase I

Indexed keywords

DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; LURTOTECAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; EARLY CANCER; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; LEUKEMIA CELL; LIFE EXPECTANCY; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCID MOUSE; SPECIES COMPARISON; SURVIVAL TIME; TAIL;

EID: 0037677433     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00092-4     Document Type: Article

References (56)

1. Beran M., Kantarjian H., O'Brien S.et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 88:1996;2473-2479.
2. Beran M., Estey E., O'Brien S.M.et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Lymphoma. 31:1998;521-531.
3. Beran M., Kantarjian H. Topotecan in the treatment of hematologic malignancies. Semin. Hematol. 35:1998;26-31.
4. Beran M., Estey E., O'Brien S.et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J. Clin. Oncol. 17:1999;2819-2830.
5. Beran M., Kantarjian H. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Semin. Hematol. 36:1999;3-10.
6. Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int. J. Hematol. 72:2000;139-150.
7. Cortes J., Estey E., Beran M.et al. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk. Lymphoma. 36:2000;479-484.
8. Kantarjian H.M., Beran M., Ellis A.et al. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 81:1993;1146-1151.
9. Kantarjian H.M., Estey E.H., Keating M.A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia. 10(Suppl. 1):1996;S4-S6.
10. Giles FJ, Keating A, Goldstone AH, et al. Acute myeloid leukemia. Hematology. Am Soc Hematol Educ Prog 2002;73-110.
11. Cohen D.P., Adams D.J., Flowers J.L.et al. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes. Leuk. Res. 23:1999;1061-1070.
12. Beran M., Pisa P., O'Brien S.et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res. 53:1993;3603-3610.
13. Beran M., Pisa P., Kantarjian H.et al. Growth of sensitive and drug-resistant human myeloid leukemia cells in SCID mice. Hematol. Pathol. 8:1994;135-154.
14. Jeha S., Kantarjian H., O'Brien S.et al. Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia. Leuk. Lymphoma. 32:1998;159-164.
15. Vey N., Giles F.J., Kantarjian H.et al. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia. Clin. Cancer Res. 6:2000;731-736.
16. Lackey K., Sternbach D.D., Croom D.K.et al. Water soluble inhibitors of topoisomerase I: quaternary salt derivatives of camptothecin. J. Med. Chem. 39:1996;713-719.
17. Luzzio M.J., Besterman J.M., Emerson D.L.et al. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem. 38:1995;395-401.
18. Emerson D.L., Besterman J.M., Brown H.R.et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res. 55:1995;603-609.
19. Emerson D.L., Bendele R., Brown E.et al. Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Clin. Cancer Res. 6:2000;2903-2912.
20. Loos W.J., Kehrer D., Brouwer E.et al. Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 738:2000;155-163.
21. Andersson B.S., Bergerheim U.S., Collins V.P.et al. KBM-3, an in vitro model of human acute myelomonocytic leukemia. Exp. Hematol. 20:1992;361-367.
22. Saiki R.K., Bugawan T.L., Horn G.T.et al. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature. 324:1986;163-166.
23. Beran M., Jeha S., O'Brien S.et al. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin. Cancer Res. 3:1997;2377-2384.
24. Kaplan E., Meier P. Nonparametric estimation for incomplete estimation. J. Am. Stat. Assoc. 53:1958;457-462.
25. Estey E., Thall P., David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother. Pharmacol. 40:1997;S9-S12.
26. Estey E. Treatment of refractory AML. Leukemia. 10:1996;932-936.
27. Vey N., Keating M., Giles F.et al. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood. 93:1999;3149-3150.
28. Terpstra W., Prins A., Visser T.et al. Conditions for engraftment of human acute myeloid leukemia (AML) in SCID mice. Leukemia. 9:1995;1573-1577.
29. Yan Y., Salomon O., McGuirk J.et al. Growth pattern and clinical correlation of subcutaneously inoculated human primary acute leukemias in severe combined immunodeficiency mice. Blood. 88:1996;3137-3146.
30. Zhong R.K., Donnenberg A.D., Shultz L.D.et al. Evaluation of monoclonal antibody-mediated anti-acute myeloid leukemia immunotherapy in a SCID/hu model. Leuk. Res. 20:1996;581-589.
31. Vey N., Kantarjian H., Tran H.et al. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia. Ann. Oncol. 10:1999;577-583.
32. Fujimori A., Harker W.G., Kohlhagen G.et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55:1995;1339-1346.
33. Minderman H., Cao S., Rustman Y.M. Rational design of irinotecan administration based on preclinical models. Oncology (Huntingt). 12:1998;22-30.
34. Desjardins J.P., Abbott E.A., Emerson D.L.et al. Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice. Anticancer Drugs. 12:2001;235-245.
35. Kehrer D.F., Bos A.M., Verweij J.et al. Phase I and pharmacologic study of liposomal lurtotecan, NX211: urinary excretion predicts hematologic toxicity. J. Clin. Oncol. 20:2002;1222-1231.
36. Mi Z., Burke T.G. Marked interspecies variations concerning the interactions of camptothecin with serum albumins: a frequency-domain fluorescence spectroscopic study. Biochemistry. 33:1994;12540-12545.
37. Calvert A.H., Grimshaw R., Poole C.et al. Randomized phase II trial of two intravenous schedules of the liposomal topoisomerase I inhibitor, NX211, in women with relapsed epithelialovarian cancer (OVCA): an NCIC CTG study [abstract]. Proc. Am. Soc. Clin. Oncol. 21:2002;208.
38. Kantarjian H. Introduction: hematological malignancies: is there a role for topoisomerase-I inhibitors? Semin. Hematol. 36:1999;1.
39. Cabanillas F. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma. Semin. Hematol. 36:1999;11-15.
40. Uckun F.M., Stewart C.F., Reaman G.et al. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood. 85:1995;2817-2828.
41. Silber R., Degar B., Costin D.et al. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood. 84:1994;3440-3446.
42. O'Brien S., Kantarjian H., Ellis A.et al. Topotecan in chronic lymphocytic leukemia. Cancer. 75:1995;1104-1108.
43. Rose P.G., Gordon N.H., Fusco N.et al. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma. Gynecol. Oncol. 78:2000;228-234.
44. Frangoul H., Ames M.M., Mosher R.B.et al. Phase I study of topotecan administered as a 21-day continuos infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin. Cancer Res. 5:1999;3956-3962.
45. Hochster H., Liebes L., Speyer J.et al. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin. Cancer Res. 3:1997;1245-1252.
46. Hochster H., Wadler S., Runowicz C.et al. Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group. J. Clin. Oncol. 17:1999;2553-2561.
47. Stevenson J.P., Scher R.M., Kosierowski R.et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur. J. Cancer. 34:1998;1358-1362.
48. Hoskins P., Eisenhauer E., Beare S.et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 16:1998;2233-2237.
49. Lilenbaum R.C., Miller A.A., Batist G.et al. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B study. J. Clin. Oncol. 16:1998;3302-3309.
50. Mainwaring P.N., Nicolson M.C., Hickish T.et al. Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy. Br. J. Cancer. 76:1997;1636-1639.
51. Kumazawa E., Jimbo T., Ochi Y.et al. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother. Pharmacol. 42:1998;210-220.
52. Gerrits C.J., Creemers G.J., Schellens J.H.et al. Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily × 5 intravenous administration. Br. J. Cancer. 73:1996;744-750.
53. Besterman J.M. Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic. Ann. N.Y. Acad. Sci. 803:1996;202-209.
54. Eckhardt S.G., Baker S.D., Eckardt J.R.et al. Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every 3 weeks. Clin. Cancer Res. 4:1998;595-604.
55. Paz-Ares L., Kunka R., DeMaria D.et al. A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion. Br. J. Cancer. 78:1998;1329-1336.
56. Stevenson J.P., DeMaria D., Sludden J.et al. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG-211 administered as a 21-day continuous infusion. Ann. Oncol. 10:1999;339-344.